# US 8,277,792 B2 · Peptides for active anti-cytokine immunization

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,277,792 B2
- Document ID: US8277792B2
- Status: Granted
- Kind: B2
- Application number: 13/362,234
- Filed: 2012-01-31
- Published: 2012-05-17
- Granted: 2012-10-02
- Earliest claimed: 2002-04-10
- Assignees: Vaxconsulting
- Inventors: Jean-Francois Zagury
- Web page: https://patentgrep.com/patent/US8277792B2

## CPC

- C07K 14/57: IFN-gamma
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- C07K 14/485: Epidermal growth factor [EGF], i.e. urogastrone
- C07K 14/495: Transforming growth factor [TGF]
- C07K 14/523: {Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2}
- C07K 14/525: Tumour necrosis factor [TNF]
- C07K 14/54: Interleukins [IL]
- C07K 14/5406: {IL-4}
- C07K 14/5409: {IL-5}
- C07K 14/5412: {IL-6}
- C07K 14/5428: {IL-10}
- C07K 14/5434: {IL-12}
- C07K 14/5437: {IL-13}
- C07K 14/5443: {IL-15}
- C07K 14/545: IL-1
- C07K 14/56: IFN-alpha
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- C07K 2299/00: Coordinates from 3D structures of peptides, e.g. proteins or enzymes
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Peptide of a size comprised between 5 and 40 amino acids, originating from a cytokine, in which at least one of its amino acids comprises at least one of its atoms separated by a distance d of less than 5 angströms from an atom of the receptor corresponding to said cytokine, the spacing d being evaluated on the basis of structural data, derivatives, immunogenic compounds comprising them, use of a peptide or peptide derivative or immunogenic compound for the preparation of a curative or preventative medicament intended for the treatment or prevention of diseases linked to an excess or to the presence of cytokines or for the treatment of an auto-immune disease and pharmaceutical compositions which contain at least one abovementioned peptide or peptide derivative or immunogenic compound as active ingredient.

## Claims

### Claim 1

An immunizing composition, comprising a pharmaceutically acceptable excipient and, as active ingredient, an isolated peptide consisting of 12 to 40 amino acid residues, said peptide originating from a human cytokine, wherein said isolated peptide comprises a sequence selected from the group consisting of SEQ ID NO:15 and SEQ ID NO:24.

### Claim 2 (depends on 1)

The immunizing composition of claim 1, wherein said peptide comprises SEQ ID NO:15.

### Claim 3 (depends on 1)

The immunizing composition of claim 1, wherein said peptide comprises SEQ ID NO:24.

### Claim 4 (depends on 1)

The immunizing composition of claim 1, wherein said peptide consists of the sequence of SEQ ID NO:15.

### Claim 5 (depends on 1)

The immunizing composition of claim 1, wherein said peptide consists of the sequence of SEQ ID NO:24.

### Claim 6

An immunizing composition, comprising a pharmaceutically acceptable excipient, and as active ingredient, an isolated peptide, wherein said peptide comprises the 17 amino acid residue sequence of SEQ ID NO:17 and is less than 30 residues in length.

### Claim 7 (depends on 6)

The immunizing composition of claim 6, wherein said peptide is less than 25 residues in length.

### Claim 8 (depends on 6)

The immunizing composition of claim 6, wherein said peptide is less than 20 residues in length.

### Claim 9 (depends on 6)

The immunizing composition of claim 6, wherein said peptide consists of the sequence of SEQ ID NO:17.
